ABSTRACT Myxomatosis is a recurrent problem on rabbit farms throughout Europe despite the success of vaccines. To identify gene variations of field and vaccine strains that may be responsible for changes in virulence, immunomodulation, and immunoprotection, the genomes of 6 myxoma virus (MYXV) strains were sequenced: German field isolates Munich-1, FLI-H, 2604, and 3207; vaccine strain MAV; and challenge strain ZA. The analyzed genomes ranged from 147.6 kb (strain MAV) to 161.8 kb (strain 3207). All sequences were affected by several mutations, covering 24 to 93 open reading frames (ORFs) and resulted in amino acid substitutions, insertions, or deletions. Only strains Munich-1 and MAV revealed the deletion of 10 ORFs (M007L to M015L) and 11 ORFs (M007L to M008.1L and M149R to M008.1R), respectively. Major differences were observed in the 27 immunomodulatory proteins encoded by MYXV. Compared to the reference strain Lausanne, strains FLI-H, 2604, 3207, and ZA showed the highest amino acid identity (Ͼ98.4%). In strains Munich-1 and MAV, deletion of 5 and 10 ORFs, respectively, was observed, encoding immunomodulatory proteins with ankyrin repeats or members of the family of serine protease inhibitors. Furthermore, putative immunodominant surface proteins with homology to vaccinia virus (VACV) were investigated in the sequenced strains. Only strain MAV revealed above-average frequencies of amino acid substitutions and frameshift mutations. Finally, we performed recombination analysis and found signs of recombination in vaccine strain MAV. Phylogenetic analysis showed a close relationship of strain MAV and the MSW strain of Californian MYXV. However, in a challenge model, strain MAV provided full protection against lethal challenges with strain ZA.
T he release of myxoma virus (MYXV) in the 1950s for the biological control of European rabbits (Oryctolagus cuniculus) in Australia and France is a welldocumented example of unprecedented virus spread and unexpected host-pathogen coevolution leading to attenuated virus strains and the natural selection of rabbits with genetic resistance to MYXV in the environment (1) (2) (3) . Despite the success of vaccines, MYXVs remain a recurrent problem on rabbit farms throughout Europe. There is not much validated information about vaccine breaks, and many problems after vaccination seem to be due to vaccine and application failures (4) . However, a surveillance of the efficacy of established vaccine strains against new field viruses is highly recommended. Today, modern sequencing techniques enable the rapid genetic characterization of large numbers of MYXV field isolates in comparison to reference strains.
MYXV is a member of the Poxviridae family. It is the type species of the genus Leporipoxvirus of the subfamily of Chordopoxvirinae, which additionally comprises Hare fibroma virus, Rabbit fibroma virus (RFV), and Squirrel fibroma virus (5) . In its evolutionary host, the North American brush rabbit (Sylvilagus bachmani) or the South American tapeti (Sylvilagus brasiliensis), MYXV causes a mild, benign infection accompanied by cutaneous fibromas restricted to the site of inoculation. However, European rabbits (Oryctolagus cuniculus) infected with MYXV develop the rapidly systemic and highly lethal disease myxomatosis. This virus is passively transmitted by mosquitoes or other biting arthropods but does not replicate within the vector.
European settlers first introduced European rabbits into Australia to satisfy their need for meat and fur in 1788. The introduction of several rabbits in 1859 resulted in the continent-wide spread of rabbits within 50 years and became responsible for major ecological damages. In order to control the rabbit population, the MYXV standard laboratory strain (SLS), isolated in Brazil, was introduced into Australia in 1950 and spread within 5 years across the entire, highly susceptible rabbit population (6) . Within 2 years after the introduction of the SLS, slightly attenuated MYXV strains emerged in the field. At the same time, the wild-rabbit population was selected for rabbits that were resistant to myxomatosis. This host-pathogen coevolution resulted in a reduction of the virulence of field strains of MYXV in wild rabbits compared to laboratory rabbits. Within a few years, less virulent strains became predominant in the field (7) . This evolutionary experiment was repeated in Europe in 1952. Like all poxviruses, MYXV possess a large, linear, double-stranded DNA genome of ϳ160 kb encapsidated within brick-shaped virions of about 200 to 300 nm. In contrast to other DNA viruses, poxvirus replication takes place exclusively in the cytoplasm of infected cells. To date, the complete genomes of 33 members of the Leporipoxvirus genus, 32 MYXV strains and 1 RFV strain (Table 1) , are available.
The first MYXV, which has been fully sequenced, was the Lausanne strain. It is considered the reference genome (8) . The genome consists of 161,777 bp with terminal inverted repeats (TIRs) of 11.5 kb. MYXV harbors 170 nonoverlapping open reading frames (ORFs). Much of the understanding of poxvirus replication was obtained from research on vaccinia virus (VACV). As with all members of the Poxviridae, 2 distinct forms of infectious virions, mature virions (MV) and enveloped virions (EV), are produced (9, 10) . In VACV, both membranes contain surface proteins providing epitopes for neutralizing antibodies. MV membrane-associated proteins also have orthologs in MYXV: A17 (MYXV M107), A27 (MYXV M115), A28 (MYXV M116), D8 (MYXV M083), H3 (MYXV M071), and L1 (MYXV M055). The same counts for the EV-specific proteins B5 (MYXV M144) and the F13L protein, referred to as p37 (MYXV M022) (11) (12) (13) .
Poxviruses reveal a high mutation rate that enables them to evolve at rates nearly as high as those of RNA viruses (14) . Therefore, it is important to investigate MYXV vaccine strains, as well as MYXV field strains, for mutations in genes encoding envelope proteins and proteins involved in immunomodulation or virulence. An effective vaccination strategy is required for successful protection from myxomatosis. Only live vaccines of attenuated MYXV provide full protection from myxomatosis. They can be divided into 2 groups. The first group of live vaccines consists of orthologous attenuated MYXV strains. Vaccine strain MAV has an unclear history, but initially, it was derived from a cell culture-attenuated Californian MSD strain (15) . The second group of vaccines consists of the closely related, nonpathogenic leporipoxvirus RFV. In RFV, 7 ORFs are missing or fragmented compared to MYXV. However, RFV is genetically and antigenically sufficiently closely related to MYXV to provide cross-protection from MYXV (16) .
The aim of this study was the examination of the genetic stability of MYXV vaccine and field strains. We generated complete genome sequences of six MYXV vaccine, challenge, and field strains (Table 2 ) and compared them in detail to those of the reference strain Lausanne, the vaccine strains SG33 and 6918, as well as RFV. The genome analysis concerned primarily virulence, host range, immunomodulating, and envelope protein-encoding genes. The phylogenetic relationship among the 6 sequenced MYXV strains, the reported RFV sequence, and all 32 available MYXV sequences was analyzed by a maximum likelihood phylogenetic analysis. The identifica- tion of nonessential gene regions that may serve for the integration of exogenous DNA for the development of vector-based vaccines may improve existing MYXV vaccines.
RESULTS AND DISCUSSION
We sequenced the complete genomes of 6 MYXV isolates: the commercial vaccine strain MAV, the challenge strain ZA, 3 field strains (Munich-1, 2604, and 3207) isolated between 1985 and 2007 from rabbits that died of myxomatosis, and field strain FLI-H, isolated from a vaccinated rabbit that also died of myxomatosis ( Table 2 ). Challenge strain ZA was used to prove the vaccine efficacy of strain MAV in animal experiments for drug approval. These six whole-genome sequences and the reported sequences of the Spanish isolate 6918 (17) and the French vaccine strain SG33 (18) were compared to the those of the Lausanne strain and RFV as a reference. First, we aligned the nucleotide sequences ORF by ORF to that of the Lausanne strain as a reference. We then checked for homopolymers and possible sequencing errors. At suspicious positions, we took a closer look at the sequencing raw data. After excluding any error, we translated the nucleotide sequences into amino acid sequences and performed an alignment. These ORF-by-ORF analyses at the amino acid level revealed several differences compared to the Lausanne strain.
The genomes of vaccine strain MAV and field strain Munich-1 revealed the most differences among the 6 sequenced strains compared to the genome of the Lausanne strain. Only these strains revealed severe truncations and deletions of several ORFs. The genome of strain MAV is 147,574 bp with an AT content of 56.15% (compared to 56.42% for the Lausanne strain and 60.46% for RFV). The genome is 14.2 kb shorter than that of strain Lausanne (161,777 bp) due to deletions in the TIR. In strain MAV, 160 of the 170 ORFs previously assigned to the Lausanne strain are present (Table 3) ; 6 are severely disrupted (Table 4 ). At the amino acid level, there are 2,783 differences involving 94 predicted proteins compared to the Lausanne strain. The differences consist of 1,307 amino acid (aa) substitutions as well as 1,455 deletions and 21 insertions that were the result of frameshift mutations. Of 160 predicted proteins, 66 (41.25%) are identical to those of the Lausanne strain, and 17 (10.63%) showed a substitution of 1 aa only (Tables 3 and 4) .
The genome of the ZA challenge strain is 161,609 bp long with an AT content of 56.46% ( Table 2 ). The genome is 168 bp shorter than that of strain Lausanne. There are 331 amino acid differences in 25 predicted MYXV proteins ( Table 3 ). All of the 170 ORFs assigned to the Lausanne strain are present, and 146 of the predicted viral proteins (85.38%) are identical to those of the Lausanne strain (Table 3 ). Compared to the Lausanne strain, we detected a substitution of 50 aa as well as a loss of 281 aa in coding regions due to frameshift mutations. The genome of the field isolate Munich-1 is 150,884 bp long with an AT content of 56.72% ( Table 2 ). The genome is 10.9 kb shorter than that of the Lausanne strain. In strain Munich-1, 160 of the 170 ORFs assigned to the Lausanne strain are present, whereas 10 ORFs are deleted and 2 are severely truncated inside or in close proximity to the left TIR. Six of the deleted ORFs encode (Tables 3 and 4 ). The genome of strain FLI-H consists of 161,790 bp with an AT content of 56.47% (Table 2 ). This genome is 13 bp longer than that of the Lausanne strain. All 170 ORFs assigned to the Lausanne strain are present. At the amino acid level, there are 382 differences in 33 predicted proteins involving 324 amino acid deletions, caused by frameshift mutations, and 58 amino acid substitutions compared to the Lausanne strain (Table 3) . Therefore, 80.7% of these predicted viral proteins are identical to those of the Lausanne strain. The genome of field strain 2604 is 161,715 bp, which is 62 bp smaller than that of the Lausanne strain. The AT content is 56.47% (Table 2 ). All 170 ORFs assigned to the Lausanne strain are present. At the amino acid level, there are 276 differences in 37 predicted viral proteins. Thus, 134 (78.36%) of these predicted viral proteins are identical to those of the Lausanne strain (Table 3) . Finally, the genome of strain 3207 is 161,799 bp, which is 22 bp longer than that of the Lausanne strain, and has an AT content of 56.47% (Table 2 ). All 170 ORFs assigned to the Lausanne strain are present. At the amino acid level, there are 1,038 differences in 36 predicted viral proteins compared to the Lausanne strain. Therefore, 135 (78.95%) of these predicted viral proteins are identical to those of the Lausanne strain (Table 3) . TIR. The genome of MYXV can be divided into 3 parts: the central part and the 2 flanking TIRs. The length of the TIR regions varies from 11,577 bp in strain Lausanne to 15,464 bp in strain MSW (19) . The left and right TIRs of strain Lausanne consist of 11,577 bp each (Table 3 ) and include 12 ORFs duplicated in each TIR. The mechanism determining the length of the TIRs is not known; however, changes in the size of the TIRs can occur readily (19) . The TIRs of field strains FLI-H, 2604, and 3207 and challenge strain ZA are slightly shorter than those of the Lausanne strain (ϳ11,450 bp each) ( Table  3) . Each TIR incorporates all homologs of the genes present in strain Lausanne. No deletions or disruptions are observed. In strain Munich-1, the boundary of the TIRs has shifted due to deletions. The M006L gene is truncated, whereas the homologs of M007L (M-T7), M008L, and M008.1L (SERP-1) are deleted compared to the Lausanne strain. Vaccine strain MAV reveals the deletion of 11 ORFs and the truncation of 3 ORFs inside or in close proximity to the left and right TIRs. Ten of the deleted ORFs encode proteins with immunomodulatory function. The TIRs consist of 7,681 bp. In the left TIR of strain MAV, the deletion spans from the beginning of M006L to the end of M009L. The In-frame fusion of truncated ORFs M151R and M001R. Immunomodulatory proteins. Poxviruses encode a vast variety of immunomodulatory proteins aimed at circumventing the host's immune defense and ensuring successful viral replication. Understanding the mechanisms by which poxviruses evade and disrupt the immune system is essential for the design and production of vaccines and therapeutics. Some of these secreted immunomodulatory proteins are already expressed in heterologous systems and used for the treatment of inflammatory conditions (29) . Immunomodulatory proteins aim at various targets in the cell and recognize immune targets in rabbits as well as in mice or humans. The predicted proteins can be divided into 6 major groups (Table 5) : MYXV proteins with antiapoptotic functions, MYXV serpins that inhibit cellular proinflammatory or proapoptotic proteases, MYXV proteins that interfere with leukocyte chemotaxis, MYXV proteins that interfere with leukocyte activation, MYXV proteins with sequence similarity to human immunodeficiency virus (HIV) proteins, and MYXV proteins with other immune functions. Compared to MYXV Lausanne, the following proteins show major differences between the sequenced strains and MYXV Lausanne.
Proteins with antiapoptotic functions. (i) Inhibition of proapoptotic molecules. Three proteins inhibit proapoptotic molecules: M-T2 (M002L/R), M011, and M146. M-T2 is a tumor necrosis factor receptor homolog (30) . In strain SG33, M002R is deleted completely, but due to the presence of M002L, the protein is still expressed. The M011L gene product prevents the loss of mitochondrial membrane potential (31) . In strains MAV and SG33, the predicted protein is severely truncated due to a premature stop codon and is 33 aa.
(ii) Inhibition of protein-protein interactions by viral ankyrin repeat proteins. M148R and M149R encode members of the ankyrin repeat (ANK) family of poxviruses involved in protein-protein interactions and encode a putative E3 ubiquitin ligase (22) . The M148 protein of strain MAV is severely truncated due to a premature stop codon and the resulting frameshift mutation. We also observed a frameshift mutation in strain 6918. The predicted protein is also severely truncated. In strain MAV, the M149 protein is missing completely, whereas in strain SG33, 63 aa are replaced. M150R encodes myxoma nuclear factor (MNF), which is critical for productive viral infection in rabbits, since its deletion generates an almost apathogenic virus that still replicates in cells (23) . In strain MAV, the ORF is deleted completely. In strain SG33, 104 amino acid substitutions are present in the resulting protein.
(iii) Inhibition of apoptosis by enhancing the degradation of cellular proteins or downregulating immune receptors. M004L/R (i.e., M004L and M004R) encodes the intracellular virulence factor M-T4. This protein modulates the inflammatory response to virus infection and inhibits the apoptosis of infected lymphocytes (32) (33) (34) in a way that is still poorly understood. In strain SG33, M004R is deleted completely. M153R encodes the endoplasmic reticulum (ER)-resident protein MV-LAP (myxoma virus leukemia-associated protein). MV-LAP acts as a ubiquitin ligase and promotes the downregulation of the surface-bound molecules major histocompatibility complex class I (MHC-I) and CD4 by targeting them for degradation within the lysosome (35) . In both vaccine strains MAV and SG33, the whole ORF is missing.
(iv) Inhibition of apoptosis by blocking host protein kinase R. The M156R protein is a structural mimic of the alpha subunit of eukaryotic translation initiation factor 2 (eIF2␣) and inhibits protein kinase R (PKR) (36) . This ORF is missing in vaccine strains MAV and SG33.
(v) MYXV serpins that inhibit cellular proinflammatory or proapoptotic proteases. M008.1L/R codes for the protein SERP-1, which belongs to the serpin family of serine protease inhibitors. Serpins are widely used in eukaryotic systems to regulate proteinase-dependent processes. SERP-1 is secreted from infected cells and downregulates the inflammatory response to virus infections by inhibiting serine proteases irreversibly. Rabbits infected with MYXV deficient in SERP-1 show inflammation, less severe secondary bacterial infections, and significant recovery at 14 days postinfection. When rechallenged with the parental MYXV, rabbits are resistant to myxomatosis (21) . M008.1L/R is missing in vaccine strain MAV (due to large deletions at the left and right ends of the genome). In strains SG33 and Munich-1, either M008.1L or M008.1R is present. The ORF encoding SERP-2 is deleted in vaccine strain MAV and severely truncated in vaccine strain SG33 due to a deletion in the right end of the genome.
(vi) MYXV proteins interfering with leukocyte chemotaxis. M007L/R encodes the IFN-␥ receptor homolog M-T7, which downregulates inflammation (20, 37) . In strains MAV, Munich-1, and SG33, one copy is deleted.
(vii) MYXV proteins that interfere with leukocyte activation. M013L encodes a pyrin domain-containing MYXV protein that binds to the inflammasome and inhibits the activation of interleukin-1␤ (IL-1␤) and IL-18 (38) . The M013 protein also inhibits cellular NF-B signaling, which regulates the secretion of proinflammatory cytokines (39) . The whole ORF is missing in strain Munich-1 and is severely truncated in strain MAV due to a premature stop codon. M154R encodes a protein with homology to the VACV M2 protein. There is little information about the VACV M2 protein since it is unique to poxviruses. The VACV M2 protein is produced early during infection and is sequestered in the ER (40) . During viral replication, high levels of viral proteins cause ER stress. To circumvent this problem, ER overload response (EOR) and unfolded-protein response (UPR) pathways become activated (41) . The M2 protein of VACV blocks an early event in the EOR pathway to ensure successful viral infection. The coding ORF M154R is deleted in both vaccine strains MAV and SG33.
(viii) MYXV proteins with sequence similarity to HIV proteins. M129R and M130R share partial sequence similarity with key proteins of HIV, which play a role in virus entry and decreased apoptosis (42, 43) . In vaccine strain MAV, 15 aa are replaced in the M129 protein (91.2% amino acid identity to the Lausanne strain), and 24 aa are replaced in the M130 protein.
(ix) MYXV proteins with other immune functions. M010L codes for a secreted epidermal growth factor, which is necessary for successful infection in vivo. M010L is missing in Munich-1. M135R is an important virulence factor of MYXV with unknown functions (44) . In strain 2604, a frameshift mutation results in the reduced amino acid identity of the M135 protein (82%) to the Lausanne strain. In strain 6918, the M135 protein is severely truncated due to a frameshift mutation. M144R shows similarity to VACV C3L and B5R, whose encoded proteins have complement-binding and structural functions, respectively (43) . We observed amino acid substitutions only in strain SG33.
Both vaccine strains MAV and SG33 reveal the deletion of 9 ORFs, whereas strain Munich-1 shows the deletion of 5 ORFs encoding proteins with immunomodulatory functions. Some deletions are shared (Table 5) . Taking a more detailed look by considering the duplication of ORFs at both ends of the genome, vaccine strain MAV reveals the absence of the immunomodulatory proteins M008.1, M149, M150, M151, M153, M154, and M156. The IFN-␥ receptor homolog is still expressed by M007R. In vaccine strain SG33, only proteins M153, M154, and M156 are missing. In strain Munich-1, proteins M10, M11, and M13 are missing.
Overall, it seems likely that the M148 protein plays an important role in the attenuation of vaccine strains MAV and SG33 as well as in Spanish field strain 6918. In strains MAV and 6918, the ORF is severely truncated due to frameshift mutations and shows 27.9% amino acid identity (strain MAV) or 65.9% a amino acid identity (strain 6918) to the Lausanne strain. In vaccine strain SG33, 32.3% of the ORF is mutated, resulting in a protein with 67.7% amino acid identity to the Lausanne strain. Previously, it was shown that the deletion of M148R results in a faster resolution of inflammation and that the M148 protein is partially localized in the nucleus (22) .
Envelope proteins. The antibodies that provide protection from MYXV are not known, whereas VACV surface proteins that provide targets for neutralizing antibodies are well known (12) . Since leporipoxviruses encode orthologs of the immunodominant envelope proteins of VACV, it can be assumed that neutralizing antibodies are also directed against these envelope proteins. Considering this, we analyzed these orthologous genes from the whole genomes of 9 leporipoxvirus strains, the 6 MYXV strains sequenced for this work (Table 2) , SG33, 6918, and RFV and compared them to that of the Lausanne strain (Table 6 ; see also Fig. S1 in the supplemental material) . Only RFV and vaccine strain MAV showed significant amounts of amino acid substitutions and deletions in the envelope proteins affecting potentially antigenic sites and transmembrane regions (Fig. S1a to S1g). One frameshift mutation was detected in MYXV MAV M083L (Fig. S1d) . This ORF codes for the M083 protein (VACV D8) and reveals a frameshift mutation due to the insertion of 2 nucleotides. The resulting protein is truncated and is only 158 aa. Due to this truncation, the transmembrane region (aa 242 to 269 in MYXV Lausanne) is lost. Considering this, it seems to be impossible for the M083 protein to be located in the envelope of strain MAV.
Obviously, these mutations do not affect vaccination efficacy since vaccination with each virus protects rabbits from myxomatosis successfully. From our in silico analyses, we cannot conclude how these mutations affect the formation of transmembrane regions and the production of neutralizing antibodies.
Vaccine efficacy. For drug approval, MYXV vaccines need to pass challenge tests to ensure both efficacy and safety. For drug approval in Germany, naive New Zealand White rabbits and those vaccinated with strain MAV (10 3.1 to 10 4.68 50% tissue culture infective doses [TCID 50 ]; n ϭ 50) were infected with the ZA challenge strain (10 6.0 TCID 50 ) at 17 to 24 days postvaccination ( Table 7) . The vaccine was considered effective if 90% of the vaccinated animals showed a protective effect and at least 90% of the naive animals revealed symptoms of myxomatosis. Clinical signs of myxomatosis were observed in nonvaccinated animals only, starting with conjunctival inflammation and resulting in swollen head, closed eyelids, and impaired respiration. These rabbits developed the first symptoms of myxomatosis at 8 to 11 days postinfection, which resulted in full myxomatosis, with a mortality rate of 100%. The vaccinated animals did not show any signs of myxomatosis except for localized small nodules at the inoculation site of challenge strain ZA. However, despite the numerous deletions, insertions, and mutations in vaccine strain MAV, the vaccinated rabbits showed full protection (100% survival) against lethal challenges with strain ZA, which is closely related to the Lausanne strain (see below). Recombination analysis and phylogenetic reconstruction. The complete genome sequences of the 6 MYXV isolates (Table 2) were combined with all reported genome sequences of leporipoxviruses (32 MYXV isolates and 1 RFV isolate) ( Table 1) isolated in Australia, Europe, and the United States. Multiple-sequence alignments of these 39 complete genomes were conducted with Clustal Omega (45, 46) . We checked the sequences of strains 2604, 3207, FLI-H, MAV, Munich-1, and ZA for signals of recombination. To this end, we determined the similarity of these sequences to the other 33 sequences by using a customized R script. The sequences reported under GenBank accession numbers JX565562 to JX565569, JX565571 to JX565584, and KC660079 to KC660085 and the sequence of strain Lausanne exhibit a pairwise distance of at least 99.91%. Therefore, we chose strain Lausanne as a representative of this group, and for this group, the 6 query sequences were compared to that of the Lausanne strain only. The obtained similarity plots are shown in Fig. S2 in the supplemental material. The query sequences can be divided into three groups by the strength of the evidence for recombination that we found.
(i) Group 1. The sequences of strains 2604 and Munich-1 show uniformly high sequence similarity to the Lausanne strain or one of the other query sequences throughout the whole genome; that is, they show no signs of recombination.
(ii) Group 2. The sequences of strains 3207, FLI-H, and ZA exhibit the same uniform, high similarity to the Lausanne strain or the other query sequences for most parts of the genome but display several drops in similarity to the other query sequences by about 0.5 to 1.5% over a length of about 1 to 1.5 kbp each. The most pronounced example of this kind of feature can be observed at around position 73000 for the sequence of strain 3207. These kinds of drops can be explained by either convergence or recombination; that is, they could be due to the virus developing a distinct biological feature, manifesting in its genome differing in the parts of the genome encoding this feature. Alternatively, these drops could be the result of recombination between a sequence similar to that of the Lausanne strain and a sequence that is as yet unsampled and slightly different from that of MYXV Lausanne. This region of lower similarity harbors genes M071L and M072L, which encode a structural protein and an RNA polymerase I (Pol I)-associated transcription factor. Interestingly, a sliding Bayes analysis performed previously by Kerr et al. (19) revealed recombination events between M076R and M080R of strains MSW and SG33. It is currently unknown why these two regions of recombination are located at nearly the same position. However, the fact that the locations of these regions do not coincide for these three sequences indicates that we are probably facing recombination.
(iii) Group 3. The sequence of strain MAV shows unequivocal signs of recombination between two sequences similar to those of strains Lausanne and MSW. No recombination with RFV was detected.
To conduct a phylogenetic analysis of the 11 sequences considered, we partitioned the genomes into six sets of coordinate intervals (denoted regions A to F), which share the same phylogenetic history for all sequences. These sets are 90,200 bp (region A), 46,400 bp (region B), 4,100 bp (region C), 3,900 bp (region D), 2,000 bp (region E), and 25,542 bp (region F), and Fig. S3 in the supplemental material shows how the 11 sequences analyzed are segmented by this partition. This is in line with the recombination pattern determined previously for strain SG33 (19) . Since the implied variance in sequence similarity is small, we neglect the alleged recombination from which strains ZA, FLI-H, and 3207 emerged. For each of these putatively recombination-free regions, we built a phylogenetic tree (Fig. 1) .
For regions A, D, and F, which comprise the majority of the genome, strain MAV appears to be a close sister group of strain Lausanne. In contrast, strain MAV is more closely related to MSW in regions B, C, and E. Since strain MAV has an unclear history, our findings of the relatedness of strain MAV and the Californian strain are in line with a statement made previously by Müller et al. (15) , who said that strain MAV was derived from a Californian MSD strain. Consequently, strain MAV is a recombinant of European and Californian strains. RFV was the most differing lineage and therefore represents an outgroup.
In this study, we sequenced and analyzed the genomes of 6 German strains and compared them to previously reported MYXV and RFV genomes. In our analyses, we Analysis of envelope proteins. The MYXV orthologs of VACV envelope proteins were analyzed by multiple-sequence alignments using MegAlign. First, potentially antigenic regions of the protein sequence, with a minimum length of 7 aa, were predicted by using the method of Kolaskar and Tongaonkar (57) . This method is based on the occurrence of hydrophobic residues (Cys, Leu, and Val) on the surface of a protein. Sites composed of 1 of these amino acids are more likely to form part of the antigenic sites. In a second step, the propensities to form transmembrane regions were calculated by using an algorithm described previously by Persson and Argos (58) . Prediction of potentially antigenic regions and calculation of propensities to form transmembrane regions were conducted with EMBOSS 1.5 (59) .
Multiple-sequence alignment and similarity analysis. Multiple-sequence alignments were performed with nucleotide sequences by using Clustal Omega (45, 46) . To perform similarity analysis (pairwise comparison of viral sequences), we used a sliding-window approach as employed in Simplot (3). As opposed to Simplot, the R script that we used indicates the genome regions in which a sequence is located compared to a large fraction composed of gaps, and the sequence is therefore excluded from the analysis of the respective genome region. We used a window size of 1,000 to smooth the distances, employing the Jukes-Cantor (JC) distance and excluding gaps for the calculation of distance. The step size for plotting was set to 200. A sequence was excluded from analysis in a window when the number of positions at which it has a gap exceeds 20% in that window.
Phylogenetic analysis. We used the MEGA 6.0 package to build phylogenetic trees of the putatively recombination-free regions of the genome. In preparation, we employed jModelTest 2.0 (60) to determine the site-wise substitution model, using Bayesian information criterion (BIC) as a selection criterion. The model selected as the best model was the transversional model plus gamma distribution (TVMϩG), i.e., a substitution model with variable base frequencies, variable transversion rates, equal transition rates, and gamma-distributed site-wise variation rates. As MEGA 6 does not allow the choice of a TVMϩG model as a site-wise substitution model, a general time-reversible model with gamma-distributed rates (GTRϩG model) was used as the best approximation. To assess the influence of model uncertainty on the phylogenetic inference (5), we constructed two trees for each of the six recombination-free regions, one using the JC model as a substitution model and the other using the GTRϩG model. As we observed a difference in the tree topology for only the shortest region (2,000 bp; nt 140601 to 142600) that we identified as being recombination free, and this difference was a minor one, we conclude that the choice of the substitution model has a negligible influence on the results of our analysis. We constructed maximum likelihood trees using a JC model with uniform rates and a GTRϩG model with five categories for the gamma distribution. The number of bootstrap replications was set to 500, and partial deletion with a site coverage cutoff of 95% was used for the gap treatment.
Ethics statement. The animal experiments for approval of the vaccine Cunivak Myxo were performed in accordance with the regulations of the German Animals Protection Act as amended on 8 August 1986 (64), which complies with European Union guidelines on the welfare of animals used in research (65) . The experiments were authorized by the government of the federal state of SachsenAnhalt (Ministry of Food, Agriculture, and Forestry) under reference numbers 25-Dr.Ju/Gr A12/91, 18 June 1991 (assessment of protection dosage; Cunivak Myxo; rabbit 01/91), and 25-Dr.Ju/Gr A13/91, 18 June 1991 (potency testing; Cunivak Myxo; rabbit 02/91).
Vaccine efficacy. Vaccine strain MAV is an approved MYXV vaccine and widely used in Germany (Cunivak Myxo). For drug approval, the recommended dose of vaccine strain MAV as well as the onset and duration of immunity were established experimentally (data not shown). Therefore, the efficacy of strain MAV in New Zealand White rabbits (Charles River GmbH, Germany) was tested in vaccinated animals (group I) compared to nonvaccinated rabbits (group II), and the test was repeated several times. The animals of group I (n ϭ 2 to 4) received 1 vaccine dose (10 3.1 to 10 4.68 TCID 50 ) of Cunivak Myxo dissolved in 1 ml of diluent for viral vaccines, which was inoculated subcutaneously into the chest wall of each rabbit. Rabbits of group II (n ϭ 2) received no vaccination. The TCID 50 was determined as described previously by Spearman and Kärber (61, 62) . Daily physical examinations were conducted on each rabbit for clinical signs of myxomatosis, e.g., conjunctival inflammation, swollen head, closed eyelids, and impaired respiration. Both groups received 1 ml (10 6.0 TCID 50 ) of challenge strain ZA inoculated into the chest wall of each rabbit subcutaneously at 17 to 24 days postvaccination. Additionally, 0.1 ml of challenge strain ZA was applied to each conjunctiva of the lower eyelid. Daily physical examinations were conducted on each rabbit until 42 days postvaccination. Accession number(s). The six new MYXV genome assemblies were submitted to GenBank and assigned accession numbers KP723386 to KP723391.
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